RAPP

Rapport Therapeutics, Inc. · NASDAQ

29.52+0.92 · +3.22%Price 10/20/2026, 11:35

staletwelve_data· Warm coverage· 10/20/2026, 11:35

The latest successful data is delayed or outside its freshness window.

Twelve Data ↗

1D 1W 1M YTD 1Y MAX

1M · −10.14 · −25.57%

staletwelve_data· Warm coverage· 10/20/2026, 11:30

The latest successful data is delayed or outside its freshness window.

Twelve Data ↗

Partial history: available bars do not yet cover all of 31 calendar days in hourly bars.

EVENTS · RAPP

SCORE ≥510

staleHimma event pipeline· 2 events for RAPP· 10/20/2026, 06:05

The latest successful data is outside its freshness window.

·Oct 20MOVE · COMPANY NEWSRAPP +6.9% after the company announced positive topline Phase 2 results for RAP-219 in bipolar mania, with the trial meeting its primary and secondary endpoints. The move outpaced the broader market and industry, consistent with this positive trial news. · U.S. SEC EDGAR ↗+3.2%

·Oct 20REGULATORY · TRIAL_DATA_POSITIVE · U.S. SEC EDGAR ↗9

·Oct 16MOVE · INDUSTRY MOVERAPP -6.8% came alongside a broad biotech selloff (industry down roughly 4%, with peers like RXRX and SLS falling even more), and no company-specific news explains the drop in our sources.−6.8%

All RAPP events in the archive →

unavailableHimma calibration· Unavailable

Probability and expected-move output is unavailable until a calibrated response is published.